Edwards Lifesciences Corp. has agreed to pay $340m in stock and cash up front and up to $350m more in milestone payments for Valtech Cardio Ltd., the developer of the Cardioband transcatheter mitral valve repair technology that can also be adapted to repair tricuspid valves.
"We saw an important opportunity to incorporate Valtech's technologies into our comprehensive heart valve repair and replacement portfolio," Edwards CEO...